gsk.com

Pipeline assets and clinical trials appendix

Q3 2026

Contents

Innovation: Pipeline growth

Clinical trials

- Respiratory, Immunology and Inflammation (RI&I)
- Oncology
- HIV
- Infectious Diseases

Glossary

Innovation: Pipeline growth

Overview of potential new vaccines and medicines

62 potential new vaccines and medicines in pipeline

RI&I
Oncology
HIV
Infectious Diseases

Phase III / Registration 21

Low carbon version of MDI[1], *Ventolin* (salbutamol)	Beta 2 adrenergic receptor agonist	Asthma^
Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated ILD[2,3]**
efimosfermin alfa (GSK6519754)	FGF21 analog*	MASH[4]**
Exdensur (depemokimab)	Long-acting anti-IL5 antibody*	COPD[5]**
felcorekibart (GSK5784283)	ULA[6]-TSLP monoclonal antibody*	Asthma**
Blenrep (belantamab mafodotin)	Anti-BCMA ADC*	Multiple myeloma^**
Jemperli (dostarlimab)	Anti-PD-1 antibody*	Rectal cancer[7]^**
Jideytro (zidesamtinib)	ROS1 inhibitor	NSCLC[8]^**
neladalkib (GSK6739060)	ALK inhibitor	NSCLC[8]^**
mocertatug rezetecan (GSK5733584)	ADC targeting B7-H4*	Gynaecologic malignancies**
risvutatug rezetecan (GSK5764227)	ADC targeting B7-H3*	ES-SCLC[9]**
velzatinib (GSK6042981)	KIT inhibitor*	Gastrointestinal stromal tumours**
Zejula (niraparib)	PARP inhibitor*	Newly diagnosed glioblastoma multiforme
cabotegravir (GSK1265744)	Integrase inhibitor	HIV**
Arexvy (RSV vaccine)	Recombinant protein, adjuvanted*	RSV adults (60+ YoA[10] China)^**
Hibsago (bepirovirsen)	Antisense oligonucleotide*	Chronic HBV[11] infection^**
Bexsero (MenB vaccine)	Recombinant protein, OMV*	Meningitis B (infants US)
GSK4178116	Live, attenuated	Varicella new seed
GSK4382276	mRNA*	Seasonal flu
GSK4406371	Live, attenuated	MMRV[12] new seed
Shingrix (GSK1437173)	Recombinant protein, adjuvanted vaccine	MACE[13, 14]

^ In registration * In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Metered dose inhaler 2. Interstitial lung disease 3. In phase II/III study 4. Metabolic dysfunction-associated steatohepatitis 5. Chronic obstructive pulmonary disease 6. Ultra-long acting 7. Neoadjuvant dMMR/MSI-H rectal cancer 8. Non-small cell lung cancer 9. Extensive-stage small-cell lung cancer 10. Years of age 11. Hepatitis B virus 12. Measles, Mumps, Rubella, and Varicella 13. Major adverse cardiovascular events 14. Phase III start planned in 2026

62 potential new vaccines and medicines in pipeline

RI&I
Oncology
HIV
Infectious Diseases

Phase II

13

camlipixant (GSK5464714)	P2X3 receptor antagonist	Irritable bowel syndrome
gatuzosiran (GSK4532990)	HSD17B13 RNA interference*	ALD[1]
ozureprubart (GSK6775388)	Anti-IgE antibody*	Food allergies
***Ojjaara/Omjjara* (momelotinib)**	JAK1, JAK2 and ACVR1 inhibitor*	Myelodysplastic syndrome**
VH3810109	Broadly neutralizing antibody*	HIV
VH4011499	Capsid protein inhibitor	HIV
VH4524184	Integrase inhibitor*	HIV
alpibectir (BVL-GSK3729098)	Ethionamide booster*	Tuberculosis
ganfeborole (GSK3036656)	Leucyl t-RNA synthetase inhibitor*	Tuberculosis
GSK4077164	Bivalent GMMA and TCV*	Invasive non-typhoidal salmonella
GSK4396687	mRNA*	COVID-19
GSK5102188	Recombinant subunit, adjuvanted	UTI[2,3]
GSK5637608	Hepatitis B virus-targeted siRNA*	Chronic HBV[4] infection

GSK

* In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Alcohol-related liver disease 2. Urinary tract infection 3. In phase I/II study 4. Hepatitis B virus

62 potential new vaccines and medicines in pipeline

RI&I
Oncology
HIV
Infectious Diseases

Phase I 28

GSK3862995	Long-acting anti-IL33 antibody	COPD[1]**
GSK4347859	Interferon pathway modulator	Systemic lupus erythematosus
GSK4527363	B-cell modulator*	Systemic lupus erythematosus
GSK4528287	Anti-IL23-IL18 bispecific antibody*	Inflammatory bowel disease
GSK4771261	Monoclonal antibody against novel kidney target	Autosomal dominant PKD[2]
GSK5926371	Anti-CD19-CD20-CD3 trispecific antibody*	Autoimmune disease**
GSK6582701	PDE3/4 inhibitor*	COPD[1]
GSK6759821	siRNA*	COPD[1]
GSK6792070 (HS235)	Activin signalling inhibitor	Pulmonary arterial hypertension[3]**
GSK6792538	Complement inhibitor*	Glomerular nephropathies
belantamab (GSK2857914)	Anti-BCMA antibody*	Multiple myeloma[3]
GSK5460025	Nucleotide excision repair targeting agent*	Solid tumours[3]
GSK5471713	AR degrader	Prostate cancer[3]
GSK5533524	ADC targeting MUC-16	Solid tumours
GSK6855547 (NVL-330)	HER2 inhibitor	NSCLC[4]
VH4367310	HIV integrase inhibitor*	HIV
VH4770359	Capsid protein inhibitor	HIV
GSK3772701	*P. falciparum* whole cell inhibitor*	Malaria
GSK3882347	FimH antagonist*	Uncomplicated UTI[5]
GSK3965193	PAPD5/PAPD7 inhibitor	Chronic HBV[6] infection
GSK4024484	*P. falciparum* whole cell inhibitor*	Malaria
GSK4424989	Recombinant/glycoconjugate vaccine*	Group A streptococcal infections
GSK4425689	Circumsporozoite protein inhibitor	Malaria
GSK5459248	Pn-MAPS30plus adults*	Pneumococcal disease
GSK5459248	Pn-MAPS30plus paediatric*	Pneumococcal disease
GSK5475152	mRNA*	Seasonal flu/COVID-19[3]
GSK5893818	Recombinant protein, adjuvanted*	RSV + hMPV[7] infection
GSK6015384	Quadrivalent GMMA/glycoconjugate vaccine	Salmonella infection

* In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Chronic obstructive pulmonary disease 2. Polycystic kidney disease 3. In phase I/II study 4. Non-small cell lung cancer 5. Urinary tract infection 6. Hepatitis B virus 7. Respiratory syncytial virus and Human metapneumovirus

Respiratory, Immunology and Inflammation pipeline

RI&I
Oncology
HIV
Infectious Diseases

Phase III / Registration

5

Low carbon version of MDI[1], *Ventolin* (salbutamol)	Beta 2 adrenergic receptor agonist	Asthma^
Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated ILD[2,3]**
efimosfermin alfa (GSK6519754)	FGF21 analog*	MASH[4]**
Exdensur (depemokimab)	Long-acting anti-IL5 antibody*	COPD[5]**
felcorekibart (GSK5784283)	ULA[6]-TSLP monoclonal antibody*	Asthma**

Phase II

3

camlipixant (GSK5464714)	P2X3 receptor antagonist	Irritable bowel syndrome
gatuzosiran (GSK4532990)	HSD17B13 RNA interference*	ALD[7]
ozureprubart (GSK6775388)	Anti-IgE antibody*	Food allergies

Phase I

10

GSK3862995	Long-acting anti-IL33 antibody	COPD[5]**
GSK4347859	Interferon pathway modulator	Systemic lupus erythematosus
GSK4527363	B-cell modulator*	Systemic lupus erythematosus
GSK4528287	Anti-IL23-IL18 bispecific antibody*	Inflammatory bowel disease
GSK4771261	Monoclonal antibody against novel kidney target	Autosomal dominant PKD[8]
GSK5926371	Anti-CD19-CD20-CD3 trispecific antibody*	Autoimmune disease**
GSK6582701	PDE3/4 inhibitor*	COPD[5]
GSK6759821	siRNA*	COPD[5]
GSK6792070 (HS235)	Activin signalling inhibitor	Pulmonary arterial hypertension[9]**
GSK6792538	Complement inhibitor*	Glomerular nephropathies

^ In registration * In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Metered dose inhaler 2. Interstitial lung disease 3. In phase II/III study 4. Metabolic dysfunction-associated steatohepatitis 5. Chronic obstructive pulmonary disease 6. Ultra-long acting 7. Alcohol-related liver disease 8. Polycystic kidney disease 9. In phase I/II study

RI&I
Oncology
HIV
Infectious Diseases

Oncology pipeline

Phase III / Registration — 8

***Blenrep* (belantamab mafodotin)**	Anti-BCMA ADC* — Multiple myeloma^**
***Jemperli* (dostarlimab)**	Anti-PD-1 antibody* — Rectal cancer[1]^**
***Jideytro* (zidesamtinib)**	ROS1 inhibitor — NSCLC[2]^**
neladalkib (GSK6739060)	ALK inhibitor — NSCLC[2]^**
mocertatug rezetecan (GSK5733584)	ADC targeting B7-H4* — Gynaecologic malignancies**
risvutatug rezetecan (GSK5764227)	ADC targeting B7-H3* — ES-SCLC[3]**
velzatinib (GSK6042981)	KIT inhibitor* — Gastrointestinal stromal tumours**
***Zejula* (niraparib)**	PARP inhibitor* — Newly diagnosed glioblastoma multiforme

Phase II — 1

***Ojjaara/Omjjara* (momelotinib)**	JAK1, JAK2 and ACVR1 inhibitor* — Myelodysplastic syndrome**

Phase I — 5

belantamab (GSK2857914)	Anti-BCMA antibody* — Multiple myeloma[4]
GSK5460025	Nucleotide excision repair targeting agent* — Solid tumours[4]
GSK5471713	AR degrader — Prostate cancer[4]
GSK5533524	ADC targeting MUC-16 — Solid tumours
GSK6855547 (NVL-330)	HER2 inhibitor — NSCLC[2]

^ In registration * In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Neoadjuvant dMMR/MSI-H rectal cancer 2. Non-small cell lung cancer 3. Extensive-stage small-cell lung cancer 4. In phase I/II study

HIV pipeline

RI&I
Oncology
HIV
Infectious Diseases

Phase III / Registration — 1

cabotegravir (GSK1265744)	Integrase inhibitor	HIV**

Phase II — 3

VH3810109	Broadly neutralizing antibody*	HIV
VH4011499	Capsid protein inhibitor	HIV
VH4524184	Integrase inhibitor*	HIV

Phase I — 2

VH4367310	HIV integrase inhibitor*	HIV
VH4770359	Capsid protein inhibitor	HIV

* In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation

RI&I
Oncology
HIV
Infectious Diseases

Infectious Diseases pipeline

Phase III / Registration

7

Arexvy **(RSV vaccine)**	Recombinant protein, adjuvanted* — RSV adults (60+ YoA[1] China)^**
Hibsago **(bepirovirsen)**	Antisense oligonucleotide* — Chronic HBV[2] infection^**
Bexsero **(MenB vaccine)**	Recombinant protein, OMV* — Meningitis B (infants US)
GSK4178116	Live, attenuated — Varicella new seed
GSK4382276	mRNA* — Seasonal flu
GSK4406371	Live, attenuated — MMRV[3] new seed
Shingrix **(GSK1437173)**	Recombinant protein, adjuvanted vaccine — MACE[4, 5]

Phase II

6

alpibectir (BVL-GSK3729098)	Ethionamide booster* — Tuberculosis
ganfeborole (GSK3036656)	Leucyl t-RNA synthetase inhibitor* — Tuberculosis
GSK4077164	Bivalent GMMA and TCV* — Invasive non-typhoidal salmonella
GSK4396687	mRNA* — COVID-19
GSK5102188	Recombinant subunit, adjuvanted — UTI[6,7]
GSK5637608	Hepatitis B virus-targeted siRNA* — Chronic HBV[4] infection

Phase I

11

GSK3772701	*P. falciparum* whole cell inhibitor* — Malaria
GSK3882347	FimH antagonist* — Uncomplicated UTI[6]
GSK3965193	PAPD5/PAPD7 inhibitor — Chronic HBV[2] infection
GSK4024484	*P. falciparum* whole cell inhibitor* — Malaria
GSK4424989	Recombinant/glycoconjugate vaccine* — Group A streptococcal infections
GSK4425689	Circumsporozoite protein inhibitor — Malaria
GSK5459248	Pn-MAPS30plus adults* — Pneumococcal disease
GSK5459248	Pn-MAPS30plus paediatric* — Pneumococcal disease
GSK5475152	mRNA* — Seasonal flu/COVID-19[7]
GSK5893818	Recombinant protein, adjuvanted* — RSV + hMPV[8] infection
GSK6015384	Quadrivalent GMMA/glycoconjugate vaccine — Salmonella infection

^ In registration * In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation
1. Years of age 2. Hepatitis B virus 3. Measles, Mumps, Rubella, and Varicella 4. Major adverse cardiovascular events 5. Phase III start planned in 2026 6. Urinary tract infection 7. In phase I/II study 8. Respiratory syncytial virus and Human metapneumovirus

Changes since Q2 2026

RI&I
Oncology
HIV
Infectious Diseases

Changes on pipeline

Progressed to Phase III/Registration

- felcorekibart: ULA[1]-TSLP monoclonal antibody, Asthma
- GSK4382276: mRNA, Seasonal flu

New to Phase I

- VH4367310: HIV integrase inhibitor, HIV
- GSK4425689: Circumsporozoite protein inhibitor, Malaria

Removed from Phase I

- GSK5458514: PSMAxCD3 T cell engaging bispecific antibody, Prostate cancer
- VH4527079: HIV entry inhibitor, HIV

Achieved pipeline catalysts

Regulatory decisions

Jemperli: rectal cancer[2]	US
Arexvy: 18+ YoA[3] IC[4]	US
Hibsago: chronic HBV[5]	US, JP
Shingrix: shingles, pre-filled syringe	JP

Regulatory submission acceptances

Ventolin (low carbon MDI[6]): asthma	EU
Jemperli: rectal cancer[2]	US

Late-stage readouts

- *Jideytro*: ARROS-1, TKI[7] treatment naïve ROS1+NSCLC[8] - Positive registrational data readout

Other news

- *Zejula*: treatment of glioma - Orphan Drug Designation (EU)
- GSK4382276: Seasonal flu - Fast Track Designation (US)
- GSK5893818: RSV + hMPV[9] infection - Fast Track Designation (US)

1. Ultra-long-acting 2. Neoadjuvant locally advanced dMMR/MSI-H rectal cancer 3. Years of age 4. Immunocompromised 5. Hepatitis B virus 6. Metered dose inhaler 7. Tyrosine kinase inhibitor 8. Non-small cell lung cancer 9. Respiratory syncytial virus and Human metapneumovirus

Upcoming pipeline catalysts: 2026 and 2027

RI&I
Oncology
HIV
Infectious Diseases

	H2 2026		H1 2027		H2 2027	
Regulatory decision	neladalkib: TKI[1] pre-treated ALK+NSCLC[2]	US	*Ventolin* (low carbon MDI[6]): asthma	EU	*Exdensur*: EGPA[4]	US, JP
			cabotegravir 3× a year PrEP[3], HIV	US	*Jemperli*[8]: rectal cancer[9]	EU
			Hibsago: chronic HBV[7] infection	EU, CN	*Jideytro*: TKI[1] treatment naïve ROS1+NSCLC[2]	US
					Arexvy: 60+ YoA[10]	CN
					Bexsero: Men B (infants)	US
Regulatory submission acceptance	*Jideytro*: TKI[1] treatment naïve ROS1+NSCLC[2]	US	*Exdensur*: EGPA[4]	US, EU, CN, JP	*Jemperli*[8]: rectal cancer[9]	EU, CN
	cabotegravir: 3× a year PrEP[3], HIV prevention	US	*Ventolin* (low carbon MDI[6]): asthma	US	cabotegravir + rilpivirine: 3× a year Treatment, HIV	US
			Jemperli[8]: rectal cancer[9]	JP	*Arexvy*: 18-59 YoA[10]	CN
			Jideytro: TKI[1] pre-treated ROS1+NSCLC[2]	EU	GSK4178116: Varicella new seed	US
			neladalkib: TKI[1] pre-treated ALK+NSCLC[2]	EU		
			Bexsero: Men B (infants)	US		
Late-stage Phase III readouts	*Exdensur*: OCEAN, EGPA[4]		*Arexvy*: 18-59 YoA[10] (China)		ris-rez: EMBOLD SCLC-301, 2L ES-SCLC[11]	
	cabotegravir: EXTEND4M, 3× a year PrEP[3], HIV prevention[5]		GSK4178116: Varicella new seed		velzatinib: StrateGIST 3, 2L GIST[12]	
					cabotegravir + rilpivirine: CUATRO, 3× a year Treatment, HIV	

1. Tyrosine kinase inhibitor 2. Non-small cell lung cancer 3. Pre-exposure prophylaxis 4. Eosinophilic granulomatosis with polyangiitis 5. Pivotal phase II study 6. Metered dose inhaler 7. Hepatitis B virus 8. Tesaro asset 9. Neoadjuvant locally advanced dMMR/MSI-H rectal cancer 10. Years of age 11. Extensive-stage small-cell lung cancer 12. Gastrointestinal stromal tumours

Designations in our pipeline

RI&I
Oncology
HIV
Infectious Diseases

Breakthrough Designation

efimosfermin alfa (GSK6519754)	FGF21 analog	MASH[1]	US, EU, CN
Jemperli[2] (dostarlimab)	Anti-PD-1 antibody*	Neoadjuvant dMMR/MSI-H rectal cancer	US
Jideytro (zidesamtinib)	ROS1 inhibitor	TKI[3] pre-treated ROS1+NSCLC[4]	US
neladalkib (GSK6739060)	ALK inhibitor	TKI[3] pre-treated ALK+NSCLC[4]	US
risvutatug rezetecan (GSK5764227)	ADC targeting B7-H3*	Relapsed or refractory ES-SCLC[5]	US, EU
risvutatug rezetecan (GSK5764227)	ADC targeting B7-H3*	Relapsed or refractory osteosarcoma	US
Hibsago (bepirovirsen)	Antisense oligonucleotide*	Chronic HBV[6] infection	US, CN
GSK5637608	Hepatitis B virus-targeted siRNA*	Chronic HBV[6] infection	CN

Fast Track

Jemperli[2] (dostarlimab)	Anti-PD-1 antibody*	Neoadjuvant dMMR/MSI-H 1L rectal cancer	
velzatinib (GSK6042981)	KIT inhibitor*	Gastrointestinal stromal tumours	
Hibsago (bepirovirsen)	Antisense oligonucleotide*	Chronic HBV[6] infection	
GSK4382276	mRNA*	Seasonal flu	
GSK5893818	Recombinant protein, adjuvanted*	RSV + hMPV[8] infection	

Orphan Drug Designation

Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated ILD[8]	US
Exdensur (depemokimab)	Long-acting anti-IL5 antibody*	Hypereosinophilic syndrome	JP
GSK4771261	Monoclonal antibody against novel kidney target	Autosomal dominant PKD[9]	US, EU
Ojjaara/ Omjjara (momelotinib)	JAK1, JAK2 and ACVR1 inhibitor	VEXAS syndrome	US, EU
Jideytro (zidesamtinib)	ROS1 inhibitor	TKI[3] pre-treated ROS1+NSCLC[4]	US
neladalkib (GSK6739060)	ALK inhibitor	TKI[3] pre-treated ALK+NSCLC[4]	US
risvutatug rezetecan (GSK5764227)	ADC targeting B7-H3*	Relapsed or refractory ES-SCLC[5]	US, EU, JP
velzatinib (GSK6042981)	KIT inhibitor*	Gastrointestinal stromal tumours	US, EU
Zejula[2] (niraparib)	PARP inhibitor*	Glioblastoma multiforme	US, EU
alpibectir (BVL-GSK3729098)	Ethionamide booster*	Tuberculosis	US, EU

Priority Review

Jemperli[2] (dostarlimab)	Anti-PD-1 antibody*	Neoadjuvant dMMR/MSI-H rectal cancer	US
neladalkib (GSK6739060)	ALK inhibitor	TKI[3] pre-treated ALK+NSCLC[4]	US
Hibsago (bepirovirsen)	Antisense oligonucleotide*	Chronic HBV[6] infection	US

Qualified Infectious Disease Product

alpibectir (BVL-GSK3729098)	Ethionamide booster*	Tuberculosis

FDA Commissioner's National Priority Voucher

Jemperli[2] (dostarlimab)	Anti-PD-1 antibody*	Neoadjuvant dMMR/MSI-H rectal cancer

12

► BREAKTHROUGH DESIGNATION

US: Expedite development and review of drugs to treat serious conditions and may demonstrate substantial improvement over available therapy. Criteria includes preliminary clinical evidence that indicates substantial improvement on clinically significant endpoint over available therapies.

China: Enhance support for development of medicines to treat serious, life-threatening disease and target an unmet medical need

5

EU (PRIME): Enhance support for development of medicines that target an unmet medical need or a product expected to bring major therapeutic advantage.

► FAST TRACK (US) – Facilitate development and expedite review of drugs to treat serious conditions, including criteria that nonclinical or clinical data demonstrate potential to address unmet medical need

17

► ORPHAN DRUG DESIGNATION – intended for treatment, diagnosis or prevention of rare diseases (US, EU, Japan)

► PRIORITY REVIEW

US: A process that directs resources to the evaluation of drugs that represent significant improvements in safety or effectiveness compared with standard applications, with a shorter User-Fee review time compared to standard review (6 months vs. 9 months)

China: Process to expedite products of major interest in terms of public health and therapeutic innovation

3

► Qualified Infectious Disease Product Designation (US) – an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections

* In-license or other alliance relationship with third party
1. Metabolic dysfunction-associated steatohepatitis 2. Tesaro asset 3. Tyrosine kinase inhibitor 4. Non-small cell lung cancer 5. Extensive-stage small-cell lung cancer 6. Hepatitis B virus 7. Respiratory syncytial virus and Human metapneumovirus 8. Interstitial lung disease 8. Polycystic kidney disease

Clinical Trials

Key Phase II and III clinical trials

Respiratory, Immunology and Inflammation

Respiratory, Immunology and Inflammation

Ventolin (low carbon version of MDI)

NCT06261957

Phase	III
Patient	Participants aged 12 years and above with asthma
Subjects	477
Treatment arms	Arm A: Salbutamol HFA-134a Arm B: Salbutamol HFA-152a
Description	A randomized, double-blind, parallel group, multi-centre study to evaluate the long-term safety of salbutamol rescue medication when administered via metered dose inhalers containing the propellant HFA-152a or reference HFA-134a
Timeline	Trial start: Q2 2024 Data reported: Q4 2025
Key endpoints	AEs
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

Benlysta (belimumab)

NCT05878717 - BLISSc-ILD

Phase	II/III
Patient	Adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
Subjects	300
Treatment arms	**Arm A**: belimumab + standard therapy **Arm B**: placebo + standard therapy
Description	A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with SSc-ILD
Timeline	Trial start: Q3 2023
Key endpoints	Absolute change from baseline in Forced Vital Capacity (FVC) millilitre (mL) at week 52
Clinicaltrials.gov	Link

NCT06572384 - BEconneCTD-ILD

Phase	III
Patient	Adults with Interstitial Lung Disease (ILD) associated with Connective Tissue Disease (CTD)
Subjects	440
Treatment arms	**Arm A**: belimumab + standard therapy **Arm B**: placebo + standard therapy
Description	A randomised, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with Interstitial Lung Disease (ILD) associated with Connective Tissue Disease (CTD)
Timeline	Trial start: Q3 2024
Key endpoints	Absolute change from baseline in Forced Vital Capacity (FVC) millilitre (mL) at week 52
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

efimosfermin alfa

NCT07221227 - ZENITH-1

Phase	III
Patient	Adults with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH)
Subjects	1200
Treatment arms	Dose level 1 of efimosfermin alfa Dose level 2 of efimosfermin alfa Placebo comparator
Description	A randomised, double-blind, placebo-controlled, 3-arm study to investigate the safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Timeline	Trial start: Q4 2025
Key end points	Improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52 Resolution of steatohepatitis reading and no worsening of MASH clinical research network fibrosis score at Week 52
Clinicaltrials.gov	Link

NCT07221188 - ZENITH-2

Phase	III
Patient	Adults with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH)
Subjects	1250
Treatment arms	Dose level 1 of efimosfermin alfa Dose level 2 of efimosfermin alfa Placebo comparator
Description	A randomised, double-blind, placebo-controlled, 3-arm study to investigate the safety and tolerability of efimosfermin alfa in participants with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH)
Timeline	Trial start: Q4 2025
Key end points	Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

efimosfermin alfa

NCT07701993 - NEBULA-1

Phase	III
Patient	Adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis
Subjects	1740
Treatment arms	Experimental: efimosfermin alfa Placebo comparator
Description	A double-blind, randomised, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis
Timeline	Trial start: Q3 2026
Key end points	Time from randomization to an adjudicated composite liver-related clinical outcome
Clinicaltrials.gov	Link

NCT07704892 - NEBULA-2

Phase	III
Patient	Adult participants with compensated cirrhosis (Stage F4 Fibrosis)
Subjects	380
Treatment arms	Part A: efimosfermin alfa or placebo Part B: efimosfermin alfa
Description	A two-part, double-blind, randomised, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (Stage F4 Fibrosis) due to metabolic dysfunction-associated steatohepatitis
Timeline	Trial start: Q3 2026
Key end points	Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

efimosfermin alfa

NCT07791043 - ALLSTAR

Phase	II
Patient	Adult participants with Alcohol-related Liver Disease (ALD)
Subjects	274
Treatment arms	Efimosfermin alfa Dose Level 1 Efimosfermin alfa Dose Level 2 Efimosfermin alfa Dose Level 3 Participants will receive placebo comparator
Description	A dose-finding, double-blind, randomized, placebo-controlled phase 2 study to evaluate the efficacy and safety of treatment with efimosfermin alfa in adult participants with Alcohol-related Liver Disease (ALD)
Timeline	Trial start: Q3 2026
Key end points	Change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM) Change from Baseline in model for end-stage liver disease (MELD) score
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

Exdensur (depemokimab)

NCT06959095 - ENDURA-1

Phase	III
Patient	Adults with COPD with type 2 inflammation
Subjects	981
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A randomised, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with type 2 inflammation
Timeline	Trial start: Q2 2025
Key endpoints	Annualized rate of moderate/severe exacerbations up to 104 weeks
Clinicaltrials.gov	Link

NCT06961214 - ENDURA-2

Phase	III
Patient	Adults with COPD with type 2 inflammation
Subjects	960
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A randomised, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with type 2 inflammation
Timeline	Trial start: Q2 2025
Key endpoints	Annualized rate of moderate/severe exacerbations up to 104 weeks
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

Exdensur (depemokimab)

NCT07177339 - VIGILANT

Phase	III
Patient	Patients with COPD with Type 2 inflammation
Subjects	1196
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A multicentre, randomised, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation
Timeline	Trial start: Q4 2025
Key endpoints	Annualized rate of moderate/severe exacerbations up to 156 weeks
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

Exdensur (depemokimab)

NCT05274750 - ANCHOR-1

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
Subjects	276
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A randomised, double-blind, parallel group trial to assess the efficacy and safety of 100 mg subcutaneous depemokimab in patients with CRSwNP
Timeline	Trial start: Q2 2022 Data reported: Q3 2024
Key endpoints	Change from baseline in total endoscopic nasal polyps (NP) score at week 52 Change from baseline in mean nasal obstruction verbal response scale (VRS) score from Week 49 through to Week 52
Clinicaltrials.gov	Link

NCT05281523 - ANCHOR-2

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
Subjects	264
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A randomised, double-blind, parallel group trial to assess the efficacy and safety of 100 mg subcutaneous depemokimab in patients with CRSwNP
Timeline	Trial start: Q2 2022 Data reported: Q3 2024
Key endpoints	Change from baseline in total endoscopic nasal polyps (NP) score at week 52 Change from baseline in mean nasal obstruction verbal response scale (VRS) score from Week 49 through to Week 52
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

Exdensur (depemokimab)

NCT05263934 - OCEAN

Phase	III
Patient	Adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard of care therapy
Subjects	163
Treatment arms	Arm A: depemokimab + placebo matching mepolizumab + SoC Arm B: mepolizumab + placebo matching depemokimab + SoC
Description	A 52-week randomised, double-blind, double-dummy, parallel-group, multicentre, non-inferiority trial to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving standard of care therapy
Timeline	Trial start: Q3 2022
Key endpoints	Number of participants with remission up to 52 weeks
Clinicaltrials.gov	Link

NCT05334368 - DESTINY

Phase	III
Patient	Adults with uncontrolled hypereosinophilic syndrome (HES) receiving standard of care therapy
Subjects	110
Treatment arms	Arm A: depemokimab + SoC Arm B: placebo + SoC
Description	A randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of depemokimab in adults with HES
Timeline	Trial start: Q3 2022
Key endpoints	Frequency of HES flares up to 52 weeks
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

felcorekibart

NCT07780643 - PERSIST ASTHMA-1

Phase	III
Patient	Participants aged 12 to 80 years with uncontrolled asthma
Subjects	514
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK5784283 (felcorekibart) as an add-on therapy in adults and adolescents with uncontrolled asthma
Timeline	Trial start: Q3 2026
Key endpoints	Annualized rate of clinically significant asthma exacerbations
Clinicaltrials.gov	Link

NCT07782996 - PERSIST ASTHMA-2

Phase	III
Patient	Participants aged 12 to 80 years with uncontrolled asthma
Subjects	370
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK5784283 (felcorekibart) as an add-on therapy in adults and adolescents with uncontrolled asthma
Timeline	Trial start: Q3 2026
Key endpoints	Annualized rate of clinically significant asthma exacerbations
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

felcorekibart

NCT07782970 - PERSIST CRSwNP-1

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps
Subjects	218
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A randomised, double-blind, parallel group phase 3 study to assess the efficacy and safety of GSK5784283 (felcorekibart) in participants with chronic rhinosinusitis with nasal polyps (CRSwNP)
Timeline	Trial start: Q3 2026
Key endpoints	Change from baseline in total endoscopic nasal polyps (NP) score at Week 52 Change from baseline in mean nasal obstruction score using Verbal Response Scale (VRS) from Week 51 through to Week 52
Clinicaltrials.gov	Link

NCT07782957 - PERSIST CRSwNP-2

Phase	III
Patient	Adults with chronic rhinosinusitis with nasal polyps
Subjects	218
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A randomised, double-blind, parallel group phase 3 study to assess the efficacy and safety of GSK5784283 (felcorekibart) in participants with chronic rhinosinusitis with nasal polyps (CRSwNP)
Timeline	Trial start: Q3 2026
Key endpoints	Change from baseline in total endoscopic nasal polyps (NP) score at Week 52 Change from baseline in mean nasal obstruction score using Verbal Response Scale (VRS) from Week 51 through to Week 52
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

felcorekibart

NCT07780669 - PERSIST COPD-1

Phase	III
Patient	Adults 40 to 80 years of age with moderate to very severe COPD
Subjects	624
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of GSK5784283 (felcorekibart) in participants 40 to 80 years of age with moderate to very severe COPD
Timeline	Trial start: Q3 2026
Key endpoints	Annualized rate of moderate or severe COPD exacerbations
Clinicaltrials.gov	Link

NCT07780656 - PERSIST COPD-2

Phase	III
Patient	Adults 40 to 80 years of age with moderate to very severe COPD
Subjects	624
Treatment arms	GSK5784283 plus standard of care Matching placebo plus standard of care
Description	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of GSK5784283 (felcorekibart) in participants 40 to 80 years of age with moderate to very severe COPD
Timeline	Trial start: Q3 2026
Key endpoints	Annualized rate of moderate or severe COPD exacerbations
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

felcorekibart

NCT06748053 - NAZARE

Phase	II
Patient	Adults aged 18 to 75 years of age with uncontrolled asthma
Subjects	307
Treatment arms	Part A: Dose finding: GSK5784283 or placebo Part B: Extended dosing: GSK5784283 or placebo
Description	A multicentre, randomised, double-blind, placebo controlled, dose finding phase 2 study of anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma.
Timeline	Trial start: Q1 2025
Key endpoints	Change from baseline in the fraction of exhaled nitric oxide (FeNO)
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

camlipixant

NCT07519395 - BALANCE

Phase	II
Patient	Adults with IBS-D and IBS-M
Subjects	420
Treatment arms	Arm 1: camlipixant dose level 1/placebo or camlipixant Arm 2: camlipixant dose level 2/placebo or camlipixant Arm 3: camlipixant dose level 3/placebo or camlipixant Comparator: placebo/placebo or camlipixant in Part B.
Description	A two-part, 26-week, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M
Timeline	Trial start: Q2 2026
Key endpoints	Change from baseline in weekly abdominal pain intensity (API) over weeks 7 to 12
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

gatuzosiran

NCT06613698 - STARLIGHT

Phase	II
Patient	Adults with alcohol-related liver disease (ALD)
Subjects	393
Treatment arms	Arm 1: GSK4532990 Dose 1 Arm 2: GSK4532990 Dose 2 Arm 3: GSK4532990 Dose 3 Arm 4: GSK4532990 Dose 4 Arm 5: Placebo
Description	A dose-finding, double-blind, placebo-controlled study to evaluate the efficacy and safety of GSK4532990 for steatohepatitis in adults with ALD
Timeline	Trial start: Q4 2024
Key endpoints	AEs, SAEs Change from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 52 (kiloPascal) Liver stiffness will be measured by vibration-controlled transient elastography (VCTE) using the FibroScan® device. Change from baseline in model for end-stage liver disease (MELD) score reduction at Week 52
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

GSK3862995 (NCFB)

NCT07201051 - VENTO

Phase	II
Patient	Adults (18-85 years) with bronchiectasis
Subjects	363
Treatment arms	Arm A: GSK3862995B at dose level 1 Arm B: GSK3862995B at dose level 2 Arm C: Placebo
Description	A randomised, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
Timeline	Trial start: Q4 2025
Key end points	Annualized rate of exacerbations
Clinicaltrials.gov	Link

Respiratory, Immunology and Inflammation

ozureprubart

NCT07220811

Phase	IIb
Patient	Participants 12 to less than 56 years of age with IgE-mediated food allergy
Subjects	100
Treatment arms	Arm 1: RPT904 (Q8W) Arm 2: RPT904 (Q12W) Arm 3: Placebo (Q8W and Q12W)
Description	Randomised, double-blind, placebo-controlled study of RPT904 as monotherapy in participants with IgE-mediated food allergy
Timeline	Trial start: Q4 2025
Key end points	Ability to consume a food without dose-limiting symptoms during a double-blind, placebo-controlled food challenge after treatment with either RPT904 or placebo
Clinicaltrials.gov	Link

Oncology

Oncology

Blenrep (belantamab mafodotin)

NCT04484623 - DREAMM-8

Phase	III
Patient	Participants with relapsed/refractory multiple myeloma (RRMM)
Subjects	302
Treatment arms	Arm A: belantamab mafodotin+ pomalidomide + dexamethasone (B-Pd) Arm B: Pomalidomide, bortezomib + dexamethasone (P-Vd)
Description	A multicentre, open-label, randomised trial to evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and dexamethasone (P-Vd)
Timeline	Trial start: Q4 2020 Primary data reported: Q1 2024
Key endpoints	PFS, MRD negativity rate, ORR, CRR, VGPR or better rate, DoR, TTBR, TTR, TTP, OS, PFS2, safety
Clinicaltrials.gov	Link

NCT06679101 - DREAMM-10

Phase	III
Patient	Newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)
Subjects	520
Treatment arms	Arm A: belantamab mafodotin + lenalidomide + dexamethasone Arm B: daratumumab + lenalidomide + dexamethasone
Description	Open label trial of belantamab mafodotin in combination with lenalidomide and dexamethasone (BRd) to evaluate if this prolongs progression free survival and /or improves minimal residual disease negative status compared with daratumumab, lenalidomide, and dexamethasone (DRd) in participants with TI-NDMM
Timeline	Trial start: Q4 2024
Key endpoints	PFS, MRD negativity rate
Clinicaltrials.gov	Link

Oncology

Blenrep (belantamab mafodotin)

NCT07227311 - DREAMM-15

Phase	II
Patient	Participants with relapsed-refractory multiple myeloma
Subjects	200
Treatment arms	belantamab mafodotin + pomalidomide + dexamethasone (BPd) belantamab mafodotin + bortezomib + dexamethasone (BVd) belantamab mafodotin + carfilzomib + dexamethasone (BKd)
Description	A multicentre, open label, non-randomised study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma
Timeline	Trial start : Q2 2026
Key end points	ORR
Clinicaltrials.gov	Link

NCT07224672 - ALANIS

Phase	II
Patient	Adult participants with newly diagnosed amyloid light chain amyloidosis
Subjects	60
Treatment arms	belantamab mafodotin + cyclophosphamide, bortezomib, and dexamethasone (CyBorD)
Description	An open-label, single-arm, proof-of-concept study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis
Timeline	Trial start anticipated: H1 2026
Key end points	Overall complete hematologic response rate
Clinicaltrials.gov	Link

Oncology

Blenrep (belantamab mafodotin)

NCT07614360 - DREAMM-16

Phase	II
Patient	Participants with relapsed-refractory multiple myeloma
Subjects	120
Treatment arms	belantamab mafodotin + bortezomib + dexamethasone (BVd)
Description	A multicenter, randomised, open-label study to evaluate the safety, efficacy and pharmacokinetics of alternative and approved dosing regimens of belantamab mafodotin in combination with bortezomib and dexamethasone (BVd) in participants with relapsed/refractory multiple myeloma
Timeline	Trial start anticipated: Q4 2026
Key end points	Incidence of G3 KVA, ORR, PK
Clinicaltrials.gov	Link

Oncology

Jemperli (dostarlimab)

NCT05855200 - AZUR-2

Phase	III
Patient	Participants with untreated T4N0 or Stage III (resectable), mismatch repair deficient/high microsatellite instability (dMMR/MSI-H) colon cancer
Subjects	892
Treatment arms	Arm A: dostarlimab Arm B: Standard of care (FOLFOX/CAPEOX) or expectant observation post surgery
Description	An open-label, randomised trial of perioperative dostarlimab monotherapy versus standard of care in participants with untreated T4N0 or Stage III dMMR/MSI-H resectable colon cancer
Timeline	Trial start: Q3 2023
Key end points	EFS assessed by Blinded Independent Central Review (BICR)
Clinicaltrials.gov	Link

NCT05723562 - AZUR-1

Phase	II
Patient	Patients with untreated stage II/III mismatch repair deficient/high microsatellite instability (dMMR/MSI-H) locally advanced rectal cancer
Subjects	154
Treatment arms	dostarlimab monotherapy
Description	A single-arm, open-label trial with dostarlimab monotherapy in participants with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
Timeline	Trial start: Q1 2023 Data reported: Q3 2026
Key endpoints	Sustained cCR for 12, 24 and 36 months, EFS at 3 years
Clinicaltrials.gov	Link

Oncology

Jemperli (dostarlimab)

NCT06567782 - AZUR-4

Phase	II
Patient	Participants with previously untreated T4N0 or stage III MMRp/MSS colon cancer
Subjects	120
Treatment arms	Arm A: dostarlimab plus CAPEOX (chemotherapy) Arm B: CAPEOX (chemotherapy)
Description	An open label, randomised study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or stage III MMRp/MSS colon cancer
Timeline	Trial start: Q1 2025
Key endpoints	Major pathological response (mPR) rate, AEs, SAEs, immune-mediated AEs, and AEs leading to death or discontinuation of study intervention and by severity
Clinicaltrials.gov	Link

NCT06256588 - JADE

Phase	III
Patient	Participants have newly diagnosed unresected locally advanced histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed "CRT" in this protocol) with curative intent and has no evidence of distant metastatic disease.
Subjects	864
Treatment arms	Arm A: dostarlimab Arm B: Placebo
Description	A randomised, double-blind, placebo-controlled study to evaluate dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma
Timeline	Trial start: Q1 2024
Key endpoints	EFS assessed by Blinded Independent Central Review (BICR)
Clinicaltrials.gov	Link

Oncology

mocertatug rezetecan

NCT07286331 - BEHOLD-Endometrial01

Phase	III
Patient	Adults with recurrent endometrial cancer
Subjects	600
Treatment arms	Experimental: GSK5733584 Comparator: Standard of care chemotherapy (paclitaxel or doxorubicin) as per investigator's discretion
Description	A randomized, open-label, multicentre, phase 3 study to investigate GSK5733584 compared with chemotherapy in participants with recurrent endometrial cancer
Timeline	Trial start : Q2 2026
Key endpoints	ORR, PFS
Clinicaltrials.gov	Link

NCT07684599 - BEHOLD-Endometrial02

Phase	III
Patient	Adults with MMRp Endometrial Cancer
Subjects	610
Treatment arms	Arm A: Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab) Arm B: Physician's choice of immunotherapy (dostarlimab or pembrolizumab)
Description	A randomized, open-label, multicentre study to investigate GSK5733584 in combination with immune checkpoint inhibition for maintenance treatment of participants with Mismatch Repair proficient (MMRp) Endometrial Cancer
Timeline	Trial start anticipated: H2 2026
Key endpoints	PFS
Clinicaltrials.gov	Link

Oncology

mocertatug rezetecan

NCT07286266 - BEHOLD-Ovarian01

Phase	III
Patient	Adults with platinum-resistant ovarian cancer
Subjects	450
Treatment arms	Experimental: GSK5733584 Comparator: Standard of care chemotherapy (paclitaxel or pegylated liposomal doxorubicin or topotecan or gemcitabine) as per investigator's choice
Description	A randomised, open-label, multicentre study to investigate GSK5733584 compared with chemotherapy in participants with platinum-resistant ovarian cancer
Timeline	Trial start: Q2 2026
Key endpoints	PFS, OS
Clinicaltrials.gov	Link

NCT07684612 - BEHOLD-Ovarian02

Phase	III
Patient	Adults with platinum-sensitive ovarian cancer
Subjects	690
Treatment arms	Experimental: mocertatug rezetecan + bevacizumab Comparator: Platinum doublet chemotherapy (carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin [PLD]) and bevacizumab, followed by bevacizumab maintenance therapy
Description	A randomized, open-label, multicentre study to investigate mocertatug rezetecan with bevacizumab compared with platinum doublet with bevacizumab in participants with platinum-sensitive ovarian cancer
Timeline	Trial start: Q3 2026
Key endpoints	PFS
Clinicaltrials.gov	Link

Oncology

mocertatug rezetecan

NCT07694427 - BEHOLD-Ovarian03

Phase	III
Patient	Adults with Non-Homologous Recombination Deficient Ovarian Cancer
Subjects	720
Treatment arms	Experimental: mocertatug rezetecan +/- bevacizumab Comparator: Active observation +/- bevacizumab
Description	A randomized, open-label, multicentre study to investigate mocertatug rezetecan with or without bevacizumab in comparison to active observation with or without bevacizumab as maintenance treatment in participants with newly diagnosed FIGO stage III/IV non-homologous recombination deficient ovarian cancer
Timeline	Trial start anticipated: H2 2026
Key endpoints	PFS
Clinicaltrials.gov	Link

Oncology

risvutatug rezetecan

NCT07099898 - EMBOLD-SCLC-301

Phase	III
Patient	Participants With Relapsed Small Cell Lung Cancer (SCLC)
Subjects	420
Treatment arms	Experimental arm: GSK5764227 Active Comparator arm: Topotecan
Description	A multicentre, randomised, open-label clinical study of GSK5764227, a B7-H3 antibody drug conjugate (ADC), compared with topotecan in participants with relapsed small cell lung cancer (SCLC)
Timeline	Trial start: Q3 2025
Key endpoints	ORR, OS, DoR, PFS, AEs, SAEs
Clinicaltrials.gov	Link

NCT07802704 - EMBOLD-Prostate-302

Phase	III
Patient	Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC)
Subjects	684
Treatment arms	Risvutatug rezetecan (Ris-Rez) Participants will receive physician's choice of best supportive/standard of care (BSC), with or without androgen receptor pathway inhibitors (ARPI)
Description	A phase 3 randomized study to evaluate the safety and efficacy of risvutatug rezetecan, a B7-H3 Antibody Drug Conjugate (ADC) in participants with metastatic castration-resistant prostate cancer
Timeline	Trial start: Q3 2026
Key endpoints	rPFS, OS
Clinicaltrials.gov	Link

Oncology

velzatinib

NCT07218926 – StrateGIST 3

Phase	III
Patient	Participants with gastrointestinal stromal tumors after imatinib therapy
Subjects	450
Treatment arms	Arm 1: velzatinib (GSK6042981) Arm 2: sunitinib
Description	A randomised, multicentre, open-label study of velzatinib (GSK6042981) versus sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) after limatinib therapy
Timeline	Trial start: Q4 2025
Key endpoints	PFS, OS
Clinicaltrials.gov	Link

NCT07585266 – StrateGIST Frontline

Phase	III
Patient	Participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors
Subjects	800
Treatment arms	Arm 1: Velzatinib Arm 2: Imatinib
Description	A randomised, multicentre, open-label study of velzatinib (GSK6042981) versus Imatinib in participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors (GIST)
Timeline	Trial start: Q3 2026
Key endpoints	PFS
Clinicaltrials.gov	Link

Oncology

Ojjaara/ Omjjara (momelotinib)

NCT06847867 - MIDAS

Phase	II
Patient	Participants with low-risk myelodysplastic syndromes (LR-MDS).
Subjects	80
Treatment arms	Arm A: Dose Optimisation: momelotinib Arm B: Dose Exploration: momelotinib
Description	A randomised, open-label, study of momelotinib in participants with anemia due to low-risk Myelodysplastic Syndrome
Timeline	Trial start: Q2 2025
Key endpoints	Percentage of participants with Red Blood Cells - transfusion independence (RBC-TI) for at least 12 weeks, rolling over 24 weeks SAEs, AEs,
Clinicaltrials.gov	Link

NCT06517875 - ODYSSEY

Phase	II
Patient	Participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced
Subjects	68
Treatment arms	momelotinib + luspatercept
Description	An open-label study to evaluate momelotinib in combination with luspatercept in participants with transfusion dependent primary or secondary myelofibrosis
Timeline	Trial start: Q1 2025
Key endpoints	Percentage of participants with TI response by Week 24, AEs, SAEs
Clinicaltrials.gov	Link

Oncology

Ojjaara/ Omjjara (momelotinib)

NCT07569081 - ATLAS

Phase	II/III
Patient	Participants with a diagnosis of VEXAS
Subjects	136
Treatment arms	Arm A: momelotinib dose level 1 + Glucocorticoids Arm B: momelotinib dose level 2 + Glucocorticoids Arm C: Placebo + Glucocorticoids
Description	A randomised, double-blind, placebo controlled adaptive study evaluating the efficacy and safety of momelotinib in participants with VEXAS Syndrome
Timeline	Trial start anticipated: Q4 2026
Key endpoints	ORR
Clinicaltrials.gov	Link

HIV

HIV

cabotegravir

NCT07650916 - CUATRO

Phase	III
Patient	Adults and adolescents with HIV who are virologically suppressed on ART
Subjects	564
Treatment arms	Experimental: CAB ULA+ RPV ULA Active Comparator: CAB LA+ RPV LA
Description	A randomised, multicentre, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of cabotegravir ultra long-acting (CAB ULA) plus rilpivirine ultra long-acting (RPV ULA) or cabotegravir long-acting plus rilpivirine long-acting in adults and adolescents with HIV who are virologically suppressed on ART
Timeline	Trial start: Q2 2026
Key endpoints	Percentage of participants with plasma HIV-RNA greater than or equal to 50 copies/mL
Clinicaltrials.gov	Link

NCT06741397 - EXTEND4M

Phase	IIb
Patient	Healthy adolescent and adult participants
Subjects	229
Treatment arms	Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB long-acting at Month 3, Month 5 and every 4 months thereafter to Month 29
Description	A single arm, repeat dose study to evaluate the pharmacokinetic profile, safety, and tolerability of a new formulation of cabotegravir long-acting injected intramuscularly Q4M in adolescent and adult participants at risk of HIV acquisition
Timeline	Trial start: Q4 2024
Key endpoints	CAB trough concentrations
Clinicaltrials.gov	Link

HIV

VH3810109

NCT05996471 - EMBRACE

Phase	IIb
Patient	Antiretroviral therapy (ART)-experienced adults living with HIV
Subjects	185
Treatment arms	Group 1: VH3810109 + cabotegravir Group 2 VH3810109 + rHuPH20 + cabotegravir Group 3: Active comparator - Participants receiving standard of care (SoC) antiretroviral therapy (ART)
Description	A multicentre, randomised, open-label, trial comparing the efficacy, safety, PK, and tolerability of VH3810109, administered either intravenously or as a subcutaneous infusion with rHuPH20, in combination with cabotegravir given intramuscularly, to standard of care in virologically suppressed, antiretroviral therapy (ART)-experienced adults living with HIV
Timeline	Trial start: Q3 2023
Key endpoints	Safety, plasma HIV-1 levels
Clinicaltrials.gov	Link

HIV

VH4011499

NCT07816250 - CINERGY

Phase	IIb
Patient	Treatment-naïve viremic adult participants with HIV-1
Subjects	200
Treatment arms	Group 1: VH4011499 dose Group 1 + cabotegravir Group 2: VH4011499 dose Group 2 + cabotegravir Group 3: VH4011499 dose Group 3 + cabotegravir Group 4: VH4011499 dose Group 4 + cabotegravir Group 5: Active comparator - Participants receiving standard of care (SoC) antiretroviral therapy (ART)
Description	
Timeline	Trial start: Q3 2023
Key endpoints	Safety, plasma HIV-1 levels
Clinicaltrials.gov	Link

HIV

VH4524184

NCT07202546 - INNOVATE

Phase	IIb
Patient	Treatment naïve persons with HIV-1
Subjects	150
Treatment arms	Experimental: VH4524184 Dose A+ emtricitabine / tenofovir alafenamide Experimental: VH4524184 Dose B + emtricitabine / tenofovir alafenamide Active Comparator: dolutegravir + 3TC Experimental: VH4524184 selected dose + emtricitabine / tenofovir alafenamide
Description	A randomised, open-label active controlled study evaluating the safety and efficacy of oral VH4524184 coadministered with emtricitabine and tenofovir alafenamide in treatment naive viremic persons with HIV-1
Timeline	Trial start: Q1 2026
Key endpoints	Percentage of participants achieving plasma HIV-1 RNA suppression
Clinicaltrials.gov	Link

Infectious diseases

Infectious diseases

Arexvy (RSV Adults)

NCT04732871 - RSV OA=ADJ-004

Phase	III
Patient	Adults ≥60 years of age
Subjects	1720
Treatment arms	Arm A: RSVPreF3 OA Day 1, 12 months & 24 months Arm B: RSVPreF3 OA Day 1 , 24 and 48 months Arm C: RSVPreF3 OA Day 1 then follow up, at month 36, re-randomization in 2 groups
Description	A randomised, open-label, multi-country trial to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above
Timeline	Trial start: Q1 2021 Primary data reported: Q2 2022
Key endpoints	Humoral immune response
Clinicaltrials.gov	Link

NCT06534892 - RSV OA=ADJ-012

Phase	IIIb
Patient	Adults aged 60 years and above
Subjects	10212
Treatment arms	RSV_PreS4: Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 4. RSV_PreS5: Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 5. RSV_1Dose: Participants in this group will not receive any additional dose of RSV PreF3 OA vaccine. Crossover: Participants in this group will receive a single dose of RSVPreF3 OA vaccine.
Description	A randomised, open label, multicountry, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study
Timeline	Trial start: Q3 2024
Key endpoints	RSV-A, RSV-B neutralization titers
Clinicaltrials.gov	Link

Infectious diseases

Arexvy (RSV Adults)

NCT07220109 - RSV OA=ADJ-028

Phase	III
Patient	Adults aged 18-59 YoA at increased risk (AIR) of RSV disease
Subjects	750
Treatment arms	China: participants 18-59 AIR , RSVPreF3 OA investigational vaccine China: participants 18-59 AIR, Placebo
Description	A study on the immune response and safety of vaccine against respiratory syncytial virus given to Chinese adults 18 to 59 years of age at increased risk of respiratory syncytial virus disease
Timeline	Trial start: Q4 2025
Key endpoints	RSV-A, RSV-B neutralization titers Seroresponse rate (SRR) in RSV-A and RSV-B neutralizing titers
Clinicaltrials.gov	Link

NCT07092865 - RSV OA=ADJ-031

Phase	II
Patient	Immunocompromised (IC) adults 18 years of age and above
Subjects	168
Treatment arms	Lung or kidney transplant recipients undergoing chronic immunosuppressive therapy who received 1 and 2 doses of the adjuvanted RSVPreF3 vaccine (IC_1 and IC_2 groups respectively) in the RSV OA=ADJ-023 parent study will receive a revaccination dose of adjuvanted RSVPreF3 vaccine at Visit 1 (Day 1) in the current study.
Description	A non-randomised, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted RSVPreF3 vaccine and the safety and immunogenicity following revaccination in lung and kidney transplant recipients (>=18 years of age)
Timeline	Trial start: Q3 2025
Key endpoints	RSV-A & -B serum neutralizing titers
Clinicaltrials.gov	Link

Infectious diseases

Hibsago (bepirovirsen)

NCT05630807 - B-WELL 1

Phase	III
Patient	Non-cirrhotic nucleos(t)ide analogue treated patients with chronic hepatitis B virus
Subjects	981
Treatment arms	Arm A: bepirovirsen for 24 weeks Arm B: placebo
Description	A multicentre, randomised, double blind trial to confirm the efficacy and safety of treatment with bepirovirsen in participants with chronic hepatitis B virus
Timeline	Trial start: Q4 2022 Data reported: Q1 2026
Key endpoints	Number of participants with baseline HBsAg≤ 3000IU/mL achieving functional cure (FC)
Clinicaltrials.gov	Link

NCT05630820 - B-WELL 2

Phase	III
Patient	Non-cirrhotic nucleos(t)ide analogue treated patients with chronic hepatitis B virus
Subjects	857
Treatment arms	Arm A: bepirovirsen for 24 weeks Arm B: placebo
Description	A multicentre, randomised, double blind trial to confirm the efficacy and safety of treatment with bepirovirsen in participants with chronic hepatitis B virus
Timeline	Trial start: Q4 2022 Data reported: Q1 2026
Key endpoints	Number of participants with baseline HBsAg≤ 3000IU/mL achieving functional cure (FC)
Clinicaltrials.gov	Link

Infectious diseases

Hibsago (bepirovirsen)

NCT06497504 - B-FOCUS

Phase	II
Patient	Participants living with human immunodeficiency virus and chronic hepatitis B virus infection on antiretroviral treatment
Subjects	153
Treatment arms	Arm A: bepirovirsen Arm B: placebo
Description	A multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of treatment with bepirovirsen in participants living with human immunodeficiency virus and chronic hepatitis B virus infection on antiretroviral treatment
Timeline	Trial start: Q3 2024
Key endpoints	Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication
Clinicaltrials.gov	Link

Infectious diseases

GSK4178116 (Varicella new seed)

NCT06693895

Phase	III
Patient	Healthy children aged 12 to 15 months
Subjects	750
Treatment arms	Participants receive 1 dose of a VNS vaccine, 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A (HAV) vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1. Participants receive 1 dose of a marketed VV, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Description	An observer-blind, randomised, controlled study to evaluate the safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age
Timeline	Trial start: Q4 2024
Key endpoints	AEs, SAEs
Clinicaltrials.gov	Link

NCT06740630

Phase	III
Patient	Healthy children 12 to 15 months of age
Subjects	1840
Treatment arms	Participants receive 1 dose of the investigational VNS vaccine of Lot 1 or Lot 2 or Lot 3, 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A vaccine (HAV), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1. Participants receive 1 dose of a marketed varicella vaccine (VV) of Lot 1 or Lot 2, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Description	An observer-blind, randomised, controlled study to demonstrate lot-to-lot consistency and evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age
Timeline	Trial start: Q1 2025
Key endpoints	Anti-glycoprotein-E antibodies at day 43
Clinicaltrials.gov	Link

Infectious diseases

GSK4178116 (Varicella new seed)

NCT06806137

Phase	III
Patient	Healthy children aged 12 to 15 months
Subjects	600
Treatment arms	Participants receive 2 doses of a VV vaccine on Day 1 and Day 91. 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A vaccine (HAV), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1. Participants receive 2 doses of a VNS vaccine on Day 1 and Day 91. 1 doses of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13, Vaxneuvance or PCV 20) on Day 1. Participants receive 1 dose of VV vaccine on Day 1, 1 dose of VNS Vaccine on Day 91. 1 doses of MMR vaccine, 1 dose of HAV, and 1 dose of PCV (either PCV 13, Vaxneuvance or PCV 20) on Day 1.
Description	An Observer-blind, randomised, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age
Timeline	Trial start: Q2 2025
Key endpoints	% of participants with seroresponse to Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) IgG and Geometric Mean Concentration (GMC) of anti-VZV gE IgG for 2 doses of VNS vaccine compared to 2 doses of VV
Clinicaltrials.gov	Link

NCT06855160

Phase	III
Patient	Healthy children 12 to 15 months of age
Subjects	911
Treatment arms	Participants receive 1 dose of the candidate varicella vaccine (VNS vaccine), 1 dose of a measles, mumps, and rubella (MMR) vaccine, 1 dose of a hepatitis A virus (HAV vaccine), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1. Participants receive 1 dose of a Marketed varicella vaccine (VV), 1 dose of a MMR vaccine, 1 dose of a HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Description	An Open-Label, randomised, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age
Timeline	Trial start: Q2 2025
Key endpoints	Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) Immunoglobulin (IgG), AEs, SAEs
Clinicaltrials.gov	Link

Infectious diseases

GSK4406371 (MMRV new seed vaccine)

NCT07406360

Phase	III
Patient	Healthy children 15 Months - 6 years of age
Subjects	1209
Treatment arms	MMRVNS MMRV
Description	A observer-blind, randomised, controlled trial to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with ProQuad when administered as a second dose to healthy children aged 15 Months -6 years of age
Timeline	Trial start: Q2 2026
Key endpoints	Anti-measles, anti-mumps, anti-rubella, and anti-glycoprotein H antibodies geometric mean concentrations
Clinicaltrials.gov	Link

Infectious diseases

GSK4077164 (iNTS S. typhimurium + S. enteritidis + S. Typhi)

NCT06213506

Phase	IIa
Patient	Adults, children and infants, including dose-finding in infants in Africa (Ghana)
Subjects	20 adults/40 children/60 infants 9 months/ 396 infants 6 weeks
Treatment arms	Stage 1: Age-de-escalation Adults (dose C or control) Children (dose B or C or control) Infants, 9 months (dose A, B, C or control) Infants, 6 months (dose A, B, C, or control) Stage 2: Dose finding in infants 6 weeks of age
Description	An observer-blind, randomised, controlled, age-de-escalation, single centre interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine against *S. typhimurium* and *S. enteritidis*, in adults, children and infants, including dose-finding in infants, in Africa (Ghana)
Timeline	Trial start: Q1 2024
Key endpoints	To evaluate the safety, reactogenicity and immunogenicity profile of iNTS-GMMA vaccine in adults, children and infants (Ghana)
Clinicaltrials.gov	Link

Infectious diseases

GSK5637608 (Chronic HBV infection)

NCT06537414 - B-UNITED

Phase	IIb
Patient	Participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy
Subjects	283
Treatment arms	Arms 1A & 2A: daplusiran/tomligisiran dose level 1 + bepirovirsen Arms 1B & 2B: daplusiran/tomligisiran dose level 2 + bepirovirsen Arm 2C: placebo + bepirovirsen
Description	A multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy
Timeline	Trial start: Q4 2024
Key end points	Number of participants achieving functional cure
Clinicaltrials.gov	Link

Glossary

Glossary

ADC	Antibody-drug conjugate
AE	Adverse event
AIR	At increased risk
ALD	Alcohol-related liver disease
ART	Antiretroviral therapy
BICR	Blinded Independent Central Review
cCR	Complete clinical response
CHMP	Committee for Medicinal Products for Human Use
CN	China
COPD	Chronic obstructive pulmonary disease
CRR	Complete response rate
CRSwNP	Chronic rhinosinusitis with nasal polyps
CTD	Connective tissue disease
dMMR	Deficient mismatch repair
DoR	Duration of response
EFS	Event-free survival
EGPA	Eosinophilic granulomatosis with polyangiitis
ES-SCLC	Extensive-stage small-cell lung cancer
EU	European Union
GIST	Gastrointestinal stromal tumor
GMMA	Generalised Modules for Membrane Antigens
HBV	Hepatitis B virus
HES	Hypereosinophilic syndrome
hMPV	Human metapneumovirus
HNSCC	Head and Neck Squamous Cell Carcinoma
IBS-D	Irritable bowel syndrome - diarrhoea
IBS-M	Irritable bowel syndrome - mixed
IC	Immunocompromised
ILD	Interstitial lung disease
iNTS	Invasive non-typhoidal salmonella
JP	Japan
MACE	Major adverse cardiovascular events
MASH	Metabolic dysfunction-associated steatohepatitis
MDI	Metered dose inhaler
MMRp	Mismatch repair proficient
MMRV	Measles, mumps, rubella and varicella
MRD	Minimal residual disease
MSI-H	Microsatellite instability high
MSS	Microsatellite stability
NSCLC	Non-small cell lung cancer
OA	Older adults
OMV	Outer membrane vesicle
ORR	Overall response rate
OS	Overall survival
PFS	Progression-free survival
PFS2	Time to second disease progression or death
PK	Pharmacokinetics
PKD	Polycystic kidney disease
PrEP	Pre-exposure prophylaxis
RRMM	Relapsed/refractory multiple myeloma
RSV	Respiratory syncytial virus
SAE	Serious adverse event
SCLC	Small cell lung cancer
siRNA	Small interfering RNA
SoC	Standard of care
SSc	Systemic sclerosis associated
TCV	Typhoid conjugate vaccine
TKI	Tyrosine kinase inhibitor
TTBR	Time to best response
TTP	Time to tumour progression
TTR	Time to treatment response
ULA	Ultra long acting
US	United States
UTI	Urinary tract infection
VGPR	Very good partial remission
VNS	Varicella new seed
YoA	Years of age